Japanese encephalitis is a viral disease. It is the leading cause of viral encephalitis in Asia, with up to 50,000 cases reported each year. The death rate among persons with symptoms of Japanese encephalitis is 30%, with another 30% having serious neurological complications. However, the risk for most travelers is very low, with fewer than 1 case per million travelers. However, rates increase for those staying for prolonged periods in areas where Japanese encephalitis is common.
Japanese encephalitis is transmitted by infected mosquitoes. When an infected mosquito bites a human, the virus is transferred. In addition, wading birds and pigs can be infected and also transfer the virus back to mosquitoes when bitten by a mosquito. Japanese encephalitis transmission occurs mainly in agricultural and rural areas, especially during summer and fall when conditions result in large amounts of standing water.
Most human infections with Japanese encephalitis do not have symptoms. However, a small percentage of those infected develop a sudden fever, headache, and vomiting about 5 to 15 days after infection. These symptoms are followed by mental status changes, neurological changes, weakness, and movement disorders. Seizures are also common, especially among children. There is no specific treatment for Japanese encephalitis. Therapy mainly consists of supportive care and management of complications. The primary public health approaches to JE prevention is through vaccination and the use of other protective measures in at-risk populations.
Currently, there is only one FDA-approved Japanese encephalitis vaccine. It is recommended for use in persons 2 months of age and older.
Product: Ixiaro® (Inactivated Japanese Encephalitis Vaccine)
Manufacturer: Intercell Biomedical
Year licensed: 2009
* To administer a 0.25 mL dose, expel and discard half of the volume from the 0.5 mL pre-filled syringe by pushing the plunger stopper up to the edge of the red line on the syringe barrel prior to injection.
To administer a 0.25 mL dose, expel and discard half of the
volume from the 0.5 mL pre-filled syringe by pushing the plunger stopper
up to the edge of the red line on the syringe barrel prior to
Individuals deploying to areas in PACOM should be administered the JE vaccine in accordance with the latest PACOM Force Health Protection guidance. Laboratory workers with potential exposure to infectious JE virus should also be vaccinated.
JE vaccination is highly recommended for Service members, DOD civilians, and beneficiaries who are stationed or who visit for more than 30 days in endemic areas. This includes those who would be based in urban areas, but likely to visit endemic rural or agricultural areas during a high-risk period of JE transmission.
JE vaccination is also recommended for Service members and beneficiaries traveling outside urban areas or who have an increased risk of exposure due to extensive outdoor activities; to an area with an ongoing JE outbreak; to endemic areas or who are uncertain about specific destinations, activities, or duration of travel.
Visit the CDC JE webpage to see a geographic distribution of the JE virus.